Economic burden of patients with leading cancers in China: a cost-of-illness study.

Simple item page
dc.citation.issue1
dc.citation.volume24
dc.contributor.authorWu Z
dc.contributor.authorYu Y
dc.contributor.authorXie F
dc.contributor.authorChen Q
dc.contributor.authorCao Z
dc.contributor.authorChen S
dc.contributor.authorLiu GG
dc.coverage.spatialEngland
dc.date.accessioned2024-12-13T01:06:34Z
dc.date.available2024-12-13T01:06:34Z
dc.date.issued2024-09-27
dc.description.abstractBACKGROUND: China accounts for 24% of newly diagnosed cancer cases and 30% of cancer-related deaths worldwide. Comprehensive analyses of the economic burden on patients across different cancer treatment phases, based on empirical data, are lacking. This study aims to estimate the financial burden borne by patients and analyze the cost compositions of the leading cancers with the highest number of new cases in China. METHODS: This cross-sectional cost-of-illness study analyzed patients diagnosed with lung, breast, colorectal, esophageal, liver, or gastric cancer, identified through electronic health records (EHRs) from 84 hospitals across 17 provinces in China. Patients completed any one of the initial treatment phase, follow-up phase, and relapse/metastasis phase were recruited by trained attending physicians through a stratified sampling procedure to ensure enough cases for each cancer progression stage and cancer treatment phase. Direct and indirect costs by treatment phase were collected from the EHRs and self-reported surveys. We estimated per case cost for each type of cancer, and employed subgroup analyses and multiple linear regression models to explore cost drivers. RESULTS: We recruited a total of 13,745 cancer patients across three treatment phases. The relapse/metastasis phase incurred the highest per case costs, varying from $8,890 to $14,572, while the follow-up phase was the least costly, ranging from $1,840 to $4,431. Being in the relapse/metastasis phase and having an advanced clinical stage of cancer at diagnosis were associated with significantly higher cost, while patients with low socioeconomic status borne lower costs. CONCLUSIONS: There were substantial financial burden on patients with six leading cancers in China. Health policymakers should emphasize comprehensive healthcare coverage for marginalized populations such as the uninsured, less educated, and those living in underdeveloped regions.
dc.description.confidentialfalse
dc.format.pagination1135-
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/39334309
dc.identifier.citationWu Z, Yu Y, Xie F, Chen Q, Cao Z, Chen S, Liu GG. (2024). Economic burden of patients with leading cancers in China: a cost-of-illness study.. BMC Health Serv Res. 24. 1. (pp. 1135-).
dc.identifier.doi10.1186/s12913-024-11514-x
dc.identifier.eissn1472-6963
dc.identifier.elements-typejournal-article
dc.identifier.issn1472-6963
dc.identifier.number1135
dc.identifier.pii10.1186/s12913-024-11514-x
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/72306
dc.languageeng
dc.publisherBioMed Central Ltd
dc.publisher.urihttps://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-024-11514-x
dc.relation.isPartOfBMC Health Serv Res
dc.rights(c) 2024 The Author/s
dc.rightsCC BY-NC-ND 4.0
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCancer costs
dc.subjectChina
dc.subjectCost-of-illness
dc.subjectTreatment phases
dc.subjectHumans
dc.subjectChina
dc.subjectCross-Sectional Studies
dc.subjectMale
dc.subjectFemale
dc.subjectMiddle Aged
dc.subjectCost of Illness
dc.subjectNeoplasms
dc.subjectAged
dc.subjectAdult
dc.subjectHealth Care Costs
dc.subjectHealth Expenditures
dc.titleEconomic burden of patients with leading cancers in China: a cost-of-illness study.
dc.typeJournal article
pubs.elements-id491834
pubs.organisational-groupCollege of Health
Files
Original bundle
Now showing 1 - 4 of 4
Thumbnail Image
Name:
Published version.pdf
Size:
1.83 MB
Format:
Adobe Portable Document Format
Description:
491834 PDF.pdf
Download
Thumbnail Image
Name:
Evidence 1.jpeg
Size:
885.19 KB
Format:
Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
Description:
12913_2024_11514_MOESM1_ESM.jpeg
Download
Thumbnail Image
Name:
Evidence 2.docx
Size:
154 KB
Format:
Microsoft Word XML
Description:
12913_2024_11514_MOESM3_ESM.docx
Download
Thumbnail Image
Name:
Evidence 3.jpeg
Size:
10.39 MB
Format:
Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
Description:
12913_2024_11514_MOESM2_ESM.jpeg
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles